InflaRx (NASDAQ:IFRX – Free Report) had its target price hoisted by Guggenheim from $7.00 to $10.00 in a report published on Wednesday morning, Ratings reports. The brokerage currently has a buy ...

HC Wainwright reissued their buy rating on shares of InflaRx (NASDAQ:IFRX – Free Report) in a report issued on Friday morning ...

Received European Commission approval for GOHIBIC® (vilobelimab) for the treatment of SARS-CoV-2-induced acute respiratory distress syndrome ...

InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, today announced the presentation of multiple posters describing the ...

Vilobelimab is a first-in-class monoclonal anti-human complement factor C5a antibody, which targets the biological activity of C5a and demonstrates high selectivity towards its target in human blood.

[This article was first published in Army Sustainment Professional Bulletin, which was then called Army Logistician, volume 2, number 5 (September–October 1970), pages 12–13. The text is ...